SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 4, 2004
INCARA PHARMACEUTICALS CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
0-50481 | 56-1953785 | |
(Commission File Number) | (IRS Employer ID Number) |
P.O. Box 14287
79 T. W. Alexander Drive
4401 Research Commons, Suite 200
Research Triangle Park, North Carolina | 27709 | |
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code (919) 558-8688
Item 5. Other Events and Regulation FD Disclosure
On May 5, 2004, Incara Pharmaceuticals Corporation (the Company) announced that it has submitted an Investigational New Drug application (IND) with the Food and Drug Administration (FDA) to begin Phase 1 clinical trials of AEOL 10150 for the possible treatment of patients with amyotrophic lateral sclerosis (also know as ALS or Lou Gehrigs disease), the resignation of its CEO, and the appointment of Dr. Shayne Gad as President. A copy of the Companys press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 7. Financial Statements and Exhibits
(c) | Exhibits |
Exhibit | 99.1 Press release dated May 5, 2004. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
INCARA PHARMACEUTICALS CORPORATION | ||
Date: May 5, 2004 |
||
/s/ Richard W. Reichow | ||
Richard W. Reichow | ||
Executive Vice President and Chief Financial Officer |